Endometrial Advancement After Rec or u-HCG Triggering

Universitair Ziekenhuis Brussel

Status and phase: Completed; Phase 4

Conditions: Infertility

Treatments: Drug: 10000 IU urinary HCG; Drug: 250 mcg recombinant HCG

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00953628

recHCG001

Details and patient eligibility

About

The purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhCG) with recombinant human chorionic gonadotropin (recHCG) for final oocyte maturation with regard to Ovarian hyperstimulation syndrome (OHSS)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.

Full description

Biopsies of endometrium were taken in different groups Pregnancy rates were compared among defferent groups

Enrollment: 130 patients

Sex: Female

Ages: 20 to 36 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Less than 36 years old
• Male or tubal infertility
• FSH<12 on day 3

Exclusion criteria

• Endometriosis stage 3 & 4

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

130 participants in 2 patient groups

o Group A=uHCG ovul trig

Active Comparator group

Description:

HCG for triggering

Treatment:

Drug: 10000 IU urinary HCG

o Group B=recHCG ovul trig

Experimental group

Description:

recombinant HCG for triggering

Treatment:

Drug: 250 mcg recombinant HCG